2020-03-24 08:30

Vitrolife evaluates measures to temporarily reduce staff costs

Vitrolife has previously announced that the company estimates that there will be a significant negative effect on the second quarter due to the reduced demand associated with the Coronavirus outbreak. The company has evaluated the situation and, if appropriate, will use the support packages in the countries concerned to temporarily reduce staff costs.

Vitrolife estimates that the Coronavirus outbreak will have a significant negative impact on the demand for IVF treatments during the second quarter. The company has evaluated the situation and, if appropriate, will use the support packages in the countries concerned to temporarily reduce staff costs without carrying out terminations. The company will evaluate these opportunities and conduct negotiations with the concerned parties. The company's intention is to end these temporary measures as soon as demand is normalised.

Gothenburg, 24 March 2020
VITROLIFE AB (publ)

Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

 

 

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 am CET on March 24, 2020.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Related links